Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Pharmacodynamics of AP214 Acetate in Patients Undergoing Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Has signed the trial specific informed consent form.~2. Patients ≥ 18 years old, male or female, not of childbearing potential (postmenopausal or permanently sterilized e.g., tubal occlusion, hysterectomy, bilateral salpingectomy), regardless of ethnicity.~3. Patients undergoing CABG, valve(s), CABG/valve and/or aortic root or ascending aortic aneurysm repair surgery.~4. Cleveland Clinic Renal Score ≥ 2 (higher than average risk for AKI).~5. EF ≥ 30%, evaluated within 2 months prior to screening visit.~Exclusion Criteria:~1. Cardiac surgery to be performed off pump without cardiopulmonary bypass.~2. Circulatory arrest in connection with aortic root or ascending aortic aneurysm repair surgery.~3. Confirmed or suspected endocarditis.~4. Requiring a reoperation on one of the valves within 3 months following the original valve surgical procedure.~5. Receiving Aprotinin during the trial, from Screening to Day 90.~6. Having undergone cardiovascular catheterization ≤ 48 hours prior to scheduled surgery.~7. Active peptic ulcer disease and gastritis.~8. Hemoccult positive stools, hematological, bleeding, and coagulation disorders.~9. Receiving dopamine at renal doses (2-4 mcg/kg/min), from Screening to Day 90.~10. S-Creatinine greater than 2.1 mg/dl.~11. Known or suspected hypersensitivity to the investigational medicinal product.~12. Known or suspected hypersensitivity to ondansetron or other selective 5-hydroxytryptamine 3 (5-HT3) receptor antagonists.~13. Current participation in any other interventional clinical trial.~14. Previously dosed with AP214.~15. Use of investigational medicinal products within the previous 6 months.~16. Body weight above 140 kg.~17. History of any organ transplant.~18. Women who are of childbearing potential, pregnant or breast-feeding.~19. Current abuse of alcohol or substance, according to the investigator's medical judgment~20. Has a mental incapacity or language barriers precluding adequate understanding of trial procedures.~21. Is considered by the Investigator unsuitable to participate in the trial for any other reason for instance due to a significant serious underlying condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AP214 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).